<DOC>
	<DOCNO>NCT02196558</DOCNO>
	<brief_summary>This study consist treatment phase ( 12 week ) extension phase ( 40 week ) . This study multicenter , open-label , uncontrolled , multiple ascend dose ( MAD ) study evaluate mainly safety tolerability 12-week repeat subcutaneous administration E6011 Japanese subject Rheumatoid Arthritis . First 12 subject enroll 100 mg group , next 12 subject enroll 200 mg group , last 9 subject enroll 400 mg group . A total 33 subject receive repeat subcutaneous administration E6011 . Subjects roll onto Extension phase continue monitor 52 week initial administration .</brief_summary>
	<brief_title>A Phase 1/2 Study E6011 Japanese Subjects With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Inclusion Criteria Subjects must meet follow criterion include study : 1 . Japanese patient age 20 64 year old time inform consent . 2 . Diagnosed rheumatoid arthritis ( RA ) meet 1987 ACR 2010 ACR/EULAR criterion . 3 . Presenting tenderness 4 joint ( 68 ) swell 4 joint ( 66 ) Screening Observation phase . 4 . Never treat nonantiTNF biologics never treat 2 antiTNF agent . 5 . Subjects great equal 0.6 mg/dL highsensitivity CRP ( hsCRP ) level great equal 28 mm/hr erythrocyte sedimentation rate ( ESR ) Screening . 6 . Weighs great equal 30 kg less equal 100 kg Screening . 7 . Consent use contraception ( subject subject 's partner ) , least 70 day last dose study medication start day inform consent , subject man capable reproduction woman childbearing potential . 8 . Has voluntarily consent , write , participate study 9 . Has thoroughly brief condition participation study , willing able comply aspect protocol . Exclusion Criteria Subjects meet follow criterion exclude study : 1 . Any history complication inflammatory arthritic disorder rheumatoid arthritis Sjogren 's syndrome . 2 . Meet Class 4 Steinbrocker functional classification . 3 . History current clinical condition , associate complication malignant tumor , lymphoma , leukemia , lymphoproliferative disease . 4 . Immunodeficiency history HIV infection 5 . Infection require hospitalization intravenous administration antibiotic within 4 week first dose study treatment , infection require oral antibiotic within 2 week first dose study treatment . 6 . History tuberculosis current complication active tuberculosis . 7 . History severe allergy ( shock , anaphylactoid symptom ) . 8 . History clinically important vascular edema , hematemesis , hemorrhagic stool , hemoptysis . 9 . History acute myocardial infarction , cerebral infarction , cerebral hemorrhage , arteriosclerosis obliterans . 10 . History clinically important vasculitis ( mononeuritis multiplex ) . 11 . Tested positive follow Screening : human immunodeficiency virus ( HIV ) , hepatitis B virus surface antigen ( HBs antigen ) , hepatitis B virus surface antibody ( HBs antibody ) , hepatitis B virus core antibody ( HBc antibody ) , hepatitis B virus DNA ( HBV DNA ) , hepatitis C virus antibody ( HCV antibody ) , human Tlymphotrophic virus Type I antibody ( HTLV1 antibody ) , syphilis . 12 . Any result negative tuberculosis test ( TSPOT.TB Test QuantiFERON TB Gold Test ) Screening . 13 . Findings indicate history tuberculosis chest Xray Screening . 14 . Ineligible participate study opinion investigator sub investigator .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Japanese subject</keyword>
</DOC>